Rocket Pharmaceuticals (RCKT) Stock Forecast & Price Target

$2.48 +0.03 (+1.22%)

Closing price 04:00 PM Eastern

Extended Trading

$2.48 0.00 (-0.20%)

As of 04:15 PM Eastern

Compare

Rocket Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 12 Analyst Ratings

Sell
2

Hold
4

Buy
6

Based on 12 Wall Street analysts who have issued ratings for Rocket Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Hold." Out of the 12 analysts, 2 have given a sell rating, 4 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for RCKT.

Consensus Price Target

$7.77
213.40% Upside

According to the 12 analysts' twelve-month price targets for Rocket Pharmaceuticals, the average price target is $7.77. The highest price target for RCKT is $15.00, while the lowest price target for RCKT is $2.95. The average price target represents a forecasted upside of 213.40% from the current price of $2.48.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for RCKT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Rocket Pharmaceuticals and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RCKT Analyst Ratings Over Time

Type	Current Forecast 11/11/25 to 11/11/26	1 Month Ago 10/12/25 to 10/12/26	3 Months Ago 8/13/25 to 8/13/26	1 Year Ago 11/11/24 to 11/11/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)	8 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)	7 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	3 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$7.77	$7.77	$8.57	$15.60
Forecasted Upside	213.40% Upside	213.40% Upside	156.63% Upside	378.53% Upside
Consensus Rating	Hold	Hold	Hold	Hold

RCKT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RCKT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Rocket Pharmaceuticals Stock vs. The Competition

Type	Rocket Pharmaceuticals	Healthcare Companies	Broader Market
Consensus Rating Score	2.42	2.32	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	217.23% Upside	111.19% Upside	14.52% Upside
News Sentiment Rating	Positive News See Recent RCKT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
11/4/2026	Weiss Ratings 2 of 5 stars		Reiterated Rating	Sell (E+)
10/8/2026	The Goldman Sachs Group 3 of 5 stars	Richard Law 5 of 5 stars	Upgrade	Sell ➝ Neutral	$3.00 ➝ $4.00	+57.48%
10/7/2026	Cantor Fitzgerald 5 of 5 stars		Reiterated Rating	Overweight
10/7/2026	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Andrew Tsai Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Hold	$2.95	+18.95%
10/7/2026	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Roanna Ruiz Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Market Perform	$7.00 ➝ $4.00	+55.95%
10/7/2026	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Yun Zhong Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Outperform
10/7/2026	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Keay Nakae Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy	$11.00	+343.55%
9/16/2026	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Gil Blum Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	Hold ➝ Buy	$9.00	+163.93%
3/30/2026	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Jason Zemansky Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$8.00 ➝ $9.00	+139.87%
2/26/2026	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings		Upgrade	Strong-Buy
Get the Latest News and Ratings for RCKT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
1/8/2026	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings		Set Target		$5.00	+32.45%
12/19/2025	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings		Upgrade	Hold
11/18/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Tessa Romero Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Neutral ➝ Underweight
7/25/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Whitney Ijem Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Buy	$11.00 ➝ $10.00	+213.97%
6/17/2025	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Colin Bristow Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Buy	$12.00 ➝ $5.00	+71.82%
5/30/2025	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Gavin Clark-Gartner Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Outperform ➝ In-Line	$5.00	+102.02%
5/28/2025	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Kostas Biliouris Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Outperform	$30.00 ➝ $8.00	+224.54%
5/28/2025	Scotiabank Subscribe to MarketBeat All Access to unlock brokerage rankings	Greg Harrison Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Sector Outperform	$51.00 ➝ $19.00	+690.02%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 05:44 PM ET.

RCKT Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Rocket Pharmaceuticals is $7.77, with a high forecast of $15.00 and a low forecast of $2.95.

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 4 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" RCKT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RCKT, but not buy additional shares or sell existing shares.

According to analysts, Rocket Pharmaceuticals's stock has a predicted upside of 213.40% based on their 12-month stock forecasts.

Over the previous 90 days, Rocket Pharmaceuticals's stock had 2 upgrades by analysts.

Rocket Pharmaceuticals has been rated by research analysts at Cantor Fitzgerald, Chardan Capital, Jefferies Financial Group, Leerink Partners, Needham & Company LLC, The Goldman Sachs Group, Wedbush, and Weiss Ratings in the past 90 days.

Analysts like Rocket Pharmaceuticals more than other "healthcare" companies. The consensus rating score for Rocket Pharmaceuticals is 2.42 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how RCKT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Rocket Pharmaceuticals Recommendations

MarketBeat monitors more than a dozen sources for Rocket Pharmaceuticals analyst ratings, with the most recent rating issued on 11/4/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket Pharmaceuticals (RCKT) Stock Forecast & Price Target

Rocket Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

RCKT Analyst Ratings Over Time

RCKT Analyst Recommendations By Month

RCKT Price Targets by Month

Rocket Pharmaceuticals Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

RCKT Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Rocket Pharmaceuticals Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rocket Pharmaceuticals (RCKT) Stock Forecast & Price Target

Rocket Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

RCKT Analyst Ratings Over Time

RCKT Analyst Recommendations By Month

RCKT Price Targets by Month

Rocket Pharmaceuticals Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

RCKT Forecast - Frequently Asked Questions

What is Rocket Pharmaceuticals' forecast for 2027?

Should I buy or sell Rocket Pharmaceuticals stock right now?

Does Rocket Pharmaceuticals's stock price have much upside?

Has Rocket Pharmaceuticals been upgraded by Wall Street analysts recently?

What analysts cover Rocket Pharmaceuticals?

Do Wall Street analysts like Rocket Pharmaceuticals more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Rocket Pharmaceuticals Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools